What is Lenapavir Sodium/Salanka used to treat?

Lenapavir sodium/Sunlenca (Sunlenca) is the first long-acting capsid inhibitor approved for HIV-1 infection (AIDS), mainly for patients who have developed resistance to multiple antiretroviral drugs. HIV is a highly mutated virus. As patients receive antiviral treatment for a long time, the probability of the virus developing drug-resistant mutations increases significantly, making many traditional drugs gradually ineffective and posing great challenges to clinical treatment. The advent of napavir sodium is precisely to solve the problem of drug resistance.

The drug’s mechanism of action is completely different from traditional reverse transcriptase inhibitors or protease inhibitors. It directly targets the capsid protein of the virus and blocks multiple key steps in the virus life cycle, including nuclear import of the viral genome and post-integration virus assembly. This new mode of action gives it a unique advantage in the treatment of drug-resistant patients and provides a new option for those HIV-infected patients who have "no drugs available."

Lenapavir sodium is suitable for adult patients, especially those who have poor response to existing antiviral drugs and have developed drug resistance. In clinical applications, it is often used in combination with other antiretroviral drugs to enhance the overall effect of treatment. Another major feature of it is that it can maintain drug efficacy through long-acting injection, thereby reducing the frequency of medication, which is of great significance to improving compliance. Inlong-term treatment of HIV, poor compliance is often an important reason for the occurrence of drug resistance. Therefore, lenapavir sodium is expected to reduce the risk of missing doses through semi-annual administration and provide patients with more reliable support for long-term control of viral load.

In general, lenapavir sodium, as an innovative achievement in HIV treatment, not only brings breakthroughs in efficacy, but also reshapes the long-term management model of HIV through changes in medication methods. As it is gradually promoted globally, lenapavir sodium is expected to become an important component of personalized HIV treatment in the future.

Reference materials:https://www.drugs.com/sunlenca.html